E Point Perfect
Law \ Legal

Celltrion USA Announces Submission of BLA for Subcutaneous Infliximab Biosimilar 


On December 22, 2022, Celltrion USA announced that it submitted a Biologics License Application (BLA) for a subcutaneous formulation of infliximab, CT-P13, to the U.S. Food and Drug Administration (FDA).  According to Celltrion, the BLA is based on phase III pivotal data that evaluated the efficacy and safety of CT-P13 as a maintenance therapy in patients with moderately to severely active ulcerative colitis and Crohn’s disease.  Results demonstrated superiority over placebo following induction therapy using an intravenous formulation of infliximab over a one-year treatment period.

Celltrion’s INFLECTRA (CT-P13) was previously approved by FDA on April 5, 2016 as an intravenous formulation.  If Celltrion’s new BLA is approved, CT-P13 would become the first subcutaneous formulation of infliximab available to patients.  Jaeik Shim, Celltrion USA’s CEO, explained that “[Celltrion is] excited about the potential of CT-P13 SC,” noting that it “releases the burden of having to travel to treatment for IV infusions, reducing treatment-related travel costs for patients and caregivers.”

The post Celltrion USA Announces Submission of BLA for Subcutaneous Infliximab Biosimilar  appeared first on Big Molecule Watch.


Source link

Related posts

Managing Leaves of Absences with Deadlines and Triggers

A food revolution is on its way; food safety and technology linked in the process

Don’t Forget to Check Your Auditor’s Certification Before Franchise Renewal Time!

Psychologists use California POST Manual: Peace Officer Psychological Screening

New Zealand Hepatitis A Outbreak linked to frozen berries jumps to 18

Unlocking Offshore Opportunities for Indian HNIs and Family Offices under the new Overseas Investment Regime